Back to search

Article

Maintenance therapy for metastatic non-squamous non-small cell lung cancer: lymphopenia as a biomarker for pemetrexed cessation

2025-08-06

Abstract excerpt

<title>Abstract</title> <p>Background A standard first-line regimen for patients with metastatic non-squamous non-small cell lung cancer (nsqNSCLC) without driver gene mutations is immune checkpoint inhibitors (ICIs) combined with pemetrexed and platinum, followed by maintenance therapy. However, the role of long-term pemetrexed maintenance remains controversial. This study evaluated the impact of pemetrexed disc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c7882c9b-48d1-5d15-9868-da9740ec74c7
DOI
10.21203/rs.3.rs-7249706/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Maintenance therapy for metastatic non-squamous non-small cell lung cancer: lymphopenia as a biomarker for pemetrexed cessationDOI 10.21203/rs.3.rs-7249706/v1
Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England.Semantic proximity
Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation.Semantic proximity
Immune Checkpoint Inhibitor without Pemetrexed for First-line Maintenance Therapy in Advanced Lung Adenocarcinoma: A real-world retrospective studySemantic proximity
Impact of Smoking on Immune Checkpoint Inhibitor Treatment Outcomes in Patients with Non-Squamous Non-Small Cell Lung Cancer with High PD-L1 Expression: A Real-World Observational StudySemantic proximity
Nivolumab as maintenance therapy following platinum-based chemotherapy in EGFR-mutant lung cancer patients after tyrosine kinase inhibitor failure: A single-arm, open-label, phase 2 trial.Semantic proximity
Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical TrialsSemantic proximity
Real-world treatment patterns and attrition for non-driver mutation metastatic non-small cell lung cancer in the US.Semantic proximity
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.Semantic proximity
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.Semantic proximity
Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysisSemantic proximity
Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity
Treatment Patterns Across Lines of Therapy for Advanced Non-Small Cell Lung Cancer in the United States.Semantic proximity
Select a neighboring publication to make it the new centre.